Amgen reported Phase 3 data in November 2026 showing clinically meaningful improvements with dazodalibep in Sjögren's disease and presented extensive new clinical and real-world evidence for Repatha ...
Source LinkAmgen reported Phase 3 data in November 2026 showing clinically meaningful improvements with dazodalibep in Sjögren's disease and presented extensive new clinical and real-world evidence for Repatha ...
Source Link
Comments